Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers

Pulmonary Pharmacology and Therapeutics · Published 2026-07-06 · DOI 10.1016/j.pupt.2026.102436

Free full text

Authors (8)

Jens M. Hohlfeld, Meike Müller, Philipp Badorrek, Laurent B. Nicolas, Oliver Vit, William G. Darby, Judith Field, Michael Larbig

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Hohlfeld, J., Müller, M., Badorrek, P., et al. (2026). Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers. Pulmonary Pharmacology and Therapeutics. https://doi.org/10.1016/j.pupt.2026.102436

Related articles